Erratum to: Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence (Surgery Today DOI: 10.1007/s00595-013-0807-y);Sub-classification of Stage II colorectal cancer based on clinicopathological risk factors for recurrence

Surgery Today

Volumn 44, Issue 5, 2014, Pages 902-905

  Hashimoto, Takuzo ^a   Itabashi, Michio ^a   Ogawa, Shinpei ^a   Hirosawa, Tomoichiro ^a   Bamba, Yoshiko ^a   Shimizu, Satoru ^a   Kameoka, Shingo ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Clinicopathological factors; Risk factors for recurrence; Stage II colorectal cancer; Sub classification

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; TUMOR INVASION;

CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899961639     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-014-0920-6     Document Type: Erratum

References (17)

1. Japanese Society for Cancer of Colon and Rectum edt. JSCCR guidelines 2010 for the treatment of colorectal cancer. Japan: Kanehara Shuppan; 2010. p. 59.
2. Kato T, Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbeck Arch Surg. 2002;386:575-81. (Pubitemid 34285637)
3. Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao T, Kodaira S. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelviclymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol. 2006;36:237-44.
4. Sakamoto J, Hamada C, Yoshida S, Kodaira S, Yasutomi M, Kato T, et al. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer. 2007;96:1170-7. (Pubitemid 46625067)
5. Akiyoshi T, Kobunai T, Watanabe T. Recent approaches to identifying biomarkers for high-risk Stage II colon cancer. Surg Today. 2012;42:1037-45.
6. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II colon cancer. J Clin Oncol. 2004;22:3408-19. (Pubitemid 41103700)
7. Van Cutsem EJ, Oliveira J, ESMO Guidelines Working Group. Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2008;19(Supplement 2):ii29-30.
8. Japanese Society for cancer of colon and Rectum edt. JSCCR guidelines 2010 for the treatment of colorectal cancer. Tokyo: Kanehara shuppan; 2010. p. 50.
9. Japanese Society for Cancer of the Colon and Rectum edt. Japanese Classification of Colorectal Carcinoma Second English Edition. Tokyo: Kanehara & Co., Ltd.
10. Haller DG, Catalano PJ, Macdonald JS, O'Rouke MA, Frontiera MS, Jackson DV, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671-8. (Pubitemid 46211510)
11. Lin CC, Lin JK, Chang SC, Wang HS, Yang SH, Jiang JK, et al. Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in single institute. Int J Colorectal Dis. 2009;24:665-76.
12. Ishizaki T, Sumi T, Yasuda Y, Shimazu M, Katumata K, Aoki T. A study of risk factors for recurrence in stage II colorectal cancer. J Jpn Surg Assoc. 2010;71:627-33.
13. Sato H, Maeda K, Sugihara K, Mochizuki H, Teramoto T, et al. High-risk stage II colon cancer after curative resection. J Surg Oncol. 2011;104:45-52.
14. Sobin LH, Wittekind Ch. TNM classification of malignant tumors, 6th edn. UICC International Union against Cancer; 2002.
15. Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM classification of malignant tumors, 7th edn. UICC International Union against Cancer; 2009.
16. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395-407. (Pubitemid 41103699)
17. Schrag D, Rifas-Shiman S, Stalz L, Bach PB, Begg CB. Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999-4005.